Abstract. Glioma is the most prevalent and fatal primary tumor of the central nervous system in adults, while the development of effective therapeutic strategies in clinical practice remain a challenge. Nucleotide-binding domain leucine-rich family pyrin-containing 3 (NLRP3) has been reported to be associated with tumorigenesis and progression; however, its expression and function in human glioma remain unclear. The present study was designed to explore the biological role and potential mechanism of NLRP3 in human glioma. The results demonstrated that overexpression of NLRP3, apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC), caspase-1 and interleukin (IL)-1β protein in human glioma tissues were significantly correlated with higher World Health Organization grades. The in vitro biological experiments demonstrated that NLRP3 downregulation significantly inhibited the proliferation, migration and invasion, and promoted the apoptosis of SHG44 and A172 glioma cell lines. Furthermore, western blot assays revealed that the downregulation of NLRP3 significantly reduced the expression of ASC, caspase-1, and IL-1β protein. Furthermore, NLRP3 knockdown caused the inhibition of epithelial-mesenchymal transition (EMT), and inhibited the phosphorylation of AKT serine/threonine kinase (AKT) and phosphorylation of phosphatase and tensin homolog (PTEN). Consistently, the upregulation of NLRP3 significantly increased the expression of ASC, caspase-1, IL-1β and phosphorylated-PTEN, promoted proliferation, migration, invasion and EMT, inhibited apoptosis, and activated the AKT signaling pathway. The data of the present study indicate that NLRP3 affects human glioma progression and metastasis through multiple pathways, including EMT and PTEN/AKT signaling pathway regulation, enhanced inflammasome activation, and undefined inflammasome-independent mechanisms. Understanding the biological effects of NLRP3 in human glioma and the underlying mechanisms may offer novel insights for the development of glioma clinical therapeutic strategies.

Introduction

Glioma is the most prevalent and fatal primary tumor of the central nervous system (CNS) in adults, accounting for 80% of all primary CNS tumors, with an annual incidence of ~6 cases/100,000 people in the United States (1). The poor outcomes for glioma patients primarily result from the malignant biological characteristics of glioma cells, including highly aggressive proliferative and invasive abilities (1,2). While persistent efforts to investigate glioma molecular oncology have achieved accumulating progress, the detailed mechanisms remain to be elucidated. Developing effective treatment therapies against specific molecular targets in human glioma remain a significant challenge (3-5).

The nucleotide-binding domain leucine-rich family pyrin-containing 3 (NLRP3) inflammasome consists of the scaffold protein NLRP3, the adaptor protein apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC) and caspase-1 (6,7). Upon activation by endogenous pathogen- and damage-associated molecular pattern molecules or exogenous irritants, the NLRP3 inflammasome is assembled, and acts as a platform for the maturation of the proinflammatory cytokines, including interleukin (IL)-1β and IL-18 (7-9). Subsequently this allows proinflammatory cytokine secretion, which promotes inflammation and immunity (7-9). The activation mechanism and function of the NLRP3 inflammasome during immuno-inflammatory responses have been widely investigated. However, accumulating studies have demonstrated that the NLRP3 inflammasome is associated with
cancer progression (10-15). Notably, certain studies reported that NLRP3 functions in an unidentified inflammasome-independent manner, whereby NLRP3 may serve independently of the production of bioactive cleaved-caspase-1 and mature IL-1β (16,17). However, the in-depth role of NLRP3 in glioma has not been well clarified.

In order to investigate the biological role of NLRP3 in glioma, the expression levels of NLRP3, as well as ASC, caspase-1 and IL-1β protein in glioma tissues were analyzed using immunohistochemical staining. Subsequently, an NLRP3-specific small interfering RNA (si-NLRP3) was constructed to deplete NLRP3 expression levels, and a plasmid system [pIRES2-enhanced green fluorescent protein (EGFP)-NLRP3] was produced for upregulating NLRP3 protein in human glioma cell lines, SHG44 and A172. In order to determine the effects of NLRP3 on malignant cellular behaviors, in vitro biological function experiments and western blot assays were performed to determine alterations to epithelial-mesenchymal transition (EMT) components, and its potential molecular mechanism in the phosphatase and tensin homolog (PTEN)/AKT serine/threonine kinase (AKT) signaling pathway, providing a novel insight into the contributions of NLRP3 to human glioma malignancy.

Materials and methods

Human glioma tissue samples. A total of 39 human glioma tissues samples were obtained from patients who underwent surgery at Nanfang Hospital, Southern Medical University (Guangzhou, China) between October 2014 and October 2015. Written informed consent was obtained from all enrolled patients. The present study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University and was performed in accordance with The Declaration of Helsinki. The age of the patients (24 male and 15 female) ranged between 11 and 80 years, with a mean age of 42±11 years. All specimens had been confirmed pathological diagnosis and classified according to the 2007 World Health Organization (WHO) classification criteria (18).

Immunohistochemical staining. The glioma specimens were fixed with 10% formalin at room temperature for 24 h and paraffin-embedded, and sectioned into 4-μm thick slices that were mounted onto microscope slides. Then, the slides were deparaffinized with xylene three times and rehydrated in a descending ethanol series (100, 95, 90, 80, 70%). Antigen retrieval was performed by heating the samples for 15 min at 95°C in citrate buffer (pH 6.0), samples were then cooled at room temperature for 30 min. The endogenous peroxidase activity was eliminated by 3% hydrogen peroxide in distilled water for 10 min at room temperature, then the slides were blocked by incubation with protein blocking solution (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) at 4°C. Following washing with PBS, Universal pre-diluted secondary antibody from the Vectastain™ ABC kit (cat. no. PK-6200; Vector Laboratories, Inc., Burlingame, CA, USA) was applied for 30 min at room temperature followed by washing with PBS. Then, the slides were incubated with the Vectastain ABC reagent for 30 min at room temperature, washed with PBS and then stained with 3,3′-diaminobenzidine using immunoperoxidase staining procedure (cat. no. SK-4105; Vector Laboratories, Inc.) according to the manufacturer’s protocol. The sections were counterstained with hematoxylin solution (cat. no. C0107; Beyotime Institute of Technology, Haimen, China) according to the manufacturer’s protocol. Images of the slides were captured under a light microscope at x100 magnification.

Cell culture and transient transfection. Human glioma SHG44 and A172 cell lines, purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China), were cultured at 37°C with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) ( Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.). Glioma cells were divided into five groups: Untransfected, si-negative control (NC), si-NLRP3, pIRES2-EGFP and pIRES2-EGFP-NLRP3 groups. To reduce endogenous NLRP3 expression, glioma cells of 70-80% confluence were transfected with 1 μg/well NLRP3-specific si-NLRP3 (cat. no. siB126155342; sequence, 5′-GGGTGGGAATTAGAC AAC-3′) or si-NC (cat. no. siN05815122147; sequence, 5′-AAG CCUCGAAAUAUCUCCU-3′) (Guangzhou RiboBio Co., Ltd., Guangzhou, China) dissolved in a transfection medium mixture of Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.) and Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) at a working concentration of 50 nM according to the manufacturer’s protocol. In parallel, for overexpression of NLRP3 in glioma cells, transfection with plasmid vectors pIRES2-EGFP-NLRP3 or the negative control pIRES2-EGFP [2 μg/well; both from Biozio Technology (Shanghai) Corporation, Ltd., Shanghai, China] was performed according to the manufacturer’s protocol. The untransfected group was only cultured with a transfection medium mixture of Opti-MEM and Lipofectamine 3000. After 6 h of transfection, the transfection medium was replaced and cells were cultured for another 24 h in DMEM with 10% FBS. The pIRES2-EGFP-NLRP3 groups were imaged at x100 magnification using an inverted phase contrast fluorescent microscope to assess GFP fluorescence. For confirmation of NLRP3 knockdown or overexpression efficiency, the cells were harvested and analyzed for NLRP3 protein expression using western blotting. The transfected glioma cells were subjected for in vitro functional experiments or western blot analysis experiments detecting molecular markers as described below.

Western blot analysis. Cells were extracted using ice-cold radio immunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology). Protein concentration in the cell lysate was determined using a bichinonic acid assay (Beyotime Institute of Biotechnology). A total of 50 μg protein/lane were loaded and separated using 10% SDS-PAGE, then transferred to polyvinylidene fluoride membranes (Merck KGaA), and...
blocked in PBS/Tween-20 containing 5% bovine serum albumin (EMD Millipore, Billerica, MA, USA) for 2 h at room temperature. Subsequently, the membranes were incubated overnight at 4°C with primary antibodies against the following: NLRP3 (cat. no. AFB23; Sigma-Aldrich; Merck KGaA; 1:2,000; rabbit Ab), ASC (cat. no. ab128097; Abcam; 1:500; mouse mAb), caspase-1 (cat. no. 2225; 1:1,000; rabbit Ab), IL-1β (cat. no. 12242; 1:1,000; mouse mAb), E-cadherin (cat. no. 3195), zonula occluden-1 (ZO-1) (cat. no. 8193), claudin-1 (cat. no. 13255), vimentin (cat. no. 5741), N-cadherin (cat. no. 13116), Snail-1 (cat. no. 3879), AKT (cat. no. 4691), phosphorylated (p)-AKT (Ser473) (cat. no. 4060), p-AKT (Thr308) (cat. no. 13038), glycogen synthase kinase-3β (GSK-3β) (cat. no. 12456), p-GSK-3β (Ser9) (cat. no. 5558), p-PTEN (Ser380) (cat. no. 9551), PTEN (cat. no. 9188) and β-actin (cat. no. 8457) (all from Cell Signaling Technology, Inc.; 1:1,000; rabbit Ab). The membranes were then incubated with the goat anti-rabbit or goat anti-mouse IgG/horseradish peroxidase-conjugated secondary antibody (anti-rabbit cat. no. bs-0295G-hrp; anti-mouse cat. no. bs-0296G-hrp; both 1:5,000; BIOSS, Beijing, China) for 1 h at room temperature. To visualize protein bands, ECL system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used. The intensity of protein bands was analyzed using ImageJ version 1.6.0 software (National Institutes of Health, Bethesda, MD, USA) and normalized by β-actin.

Colonies were counted under a light microscope and the images were captured using a digital camera.

Cell migration and invasion assays. Cell migration and invasion assays were performed using 24-well Transwell chambers with 8-µm pore size polycarbonate membrane (Corning, Cambridge, MA, USA). The transfected cells were cultured for 48 h and then 5x10^4 cells were seeded on the top side of the membrane without Matrigel for the cell migration assay or pre-coated with Matrigel (BD Biosciences) for the cell invasion assay. A total of 500 µl DMEM containing 20% FBS was added to the lower chambers. Following incubation in 12 h for the migration assay or 48 h for the invasion assay, cells inside the upper chamber were removed with cottons swabs. Migrated and invaded glioma cells attached to the lower membrane surface were fixed with 75% methanol for 30 min at room temperature, and then stained for 30 min with crystal violet at room temperature. Five random fields of view at x100 magnification were counted in each well under a light microscope and expressed as the mean number of migrated or invaded cells. Three independent assays were performed.

Statistical analysis. Data are presented as the mean ± standard deviation. Statistical analyses were performed with SPSS software version 13.0 (SPSS, Inc., Chicago, IL, USA). Spearman’s correlation coefficient was used to assess the correlation between protein expression levels and glioma WHO grades. Student’s t-tests were used to compare data variances between two groups, and one-way analysis of variance with the Dunnett’s post hoc test was used to compare difference among multiple groups. P<0.05 (two-tailed) was considered to indicate a statistically significant difference.

Results

High expression levels of NLRP3, ASC, caspase-1 and IL-1β are correlated with glioma WHO grade. NLRP3, ASC, caspase-1 and IL-1β protein compose the NLRP3 inflammasome. Immunohistochemical detection of human glioma tissue sections revealed that NLRP3, ASC, caspase-1 and IL-1β protein expression levels were all upregulated in high-grade glioma (WHO III and IV) tissue samples compared with low-grade glioma (WHO I and II) tissue, as presented in...
Fig. 1A. Statistical analysis confirmed significantly positive correlations between NLRP3, ASC, caspase-1 and IL-1β protein expression levels, and the histological grades of human glioma (Fig. 1B), indicating an important role for NLRP3 in glioma malignancy.

**Verification of NLRP3 downregulation and overexpression efficiencies in glioma cells.** To evaluate the role of NLRP3 in the malignant biological properties of glioma, siRNA-NLRP3 and the plasmid vector pIRES2-EGFP-NLRP3 were constructed to downregulate and upregulate NLRP3 expression, respectively, in glioma cell lines SHG44 and A172. The plasmid vector pIRES2-EGFP-NLRP3 exhibited a transfection efficiency of >80% in SHG44 and A172 glioma cells as indicated by GFP fluorescence (Fig. 2A). Western blot analysis verified a significant reduction in NLRP3 protein levels following the transfection of si-NLRP3 compared with si-NC (Fig. 2B and C). Furthermore, pIRES2-EGFP-NLRP3 transfection resulted in a significant increase in NLRP3 expression compared with the corresponding untransfected and pIRES2-EGFP control groups. These results confirmed the efficiency of si-NLRP3 and pIRES2-EGFP-NLRP3 for
use in the NLRP3 downregulation or overexpression in vitro functional experiments in glioma cells.

**Facilitative effects of NLRP3 on the proliferation of glioma cells.** The effect of NLRP3 on cell proliferation was assessed using colony formation, CCK-8 and EdU assays. In glioma SHG44 and A172 cell lines, downregulation of NLRP3 significantly suppressed colony formation, whereas overexpression of NLRP3 using pIRES2-EGFP-NLRP3 significantly promoted colony formation compared with the corresponding untransfected and negative control groups (Fig. 3A). Then, the growth effects of NLRP3 on human glioma cell lines were evaluated using CCK-8 assays. The si-NLRP3 groups demonstrated a significant reduction in cell viability compared with si-NC group, while NLRP3 overexpression significantly increased the viabilities of human glioma cell lines compared with the pIRES2-EGFP control groups in a time-dependent manner (Fig. 3B). Furthermore, similar effects on cell proliferation were confirmed using an EdU assay. The ratio of EdU-positive cells to total cell nuclei was used to determine the cell proliferation rate. The results revealed that the cell proliferation rate in the si-NLRP3 group was significantly reduced compared with the scramble si-NC group (Fig. 3C). Furthermore, pIRES2-EGFP-NLRP3 transfection significantly increased
the cell proliferation rate compared with pIRES2-EGFP group in SHG44 and A172 glioma cells (Fig. 3C).

**Inhibitory effects of NLRP3 on glioma cell apoptosis.** To further investigate the effect of NLRP3 on the cell apoptosis, Annexin V-APC and 7-AAD staining of human glioma cells was performed, and the apoptosis rate of each group was measured by flow cytometry after 48 h of transfection. Downregulation of NLRP3 by si-NLRP3 significantly induced apoptosis of SHG44 and A172 glioma cell lines compared with the si-NC group (Fig. 4). Following overexpression of NLRP3, the apoptosis rates of pIRES2-EGFP-NLRP3 groups were significantly reduced compared with that of the pIRES2-EGFP groups in SHG44 and A172 glioma cells (Fig. 4).

**NLRP3 promotes glioma cell migration and invasion.** To explore the effect of NLRP3 on glioma cell migration and invasion, wound healing assays, and Transwell migration and invasion assays were performed. The wound healing assays demonstrated that the migratory ability of glioma cells was significantly suppressed following transfection of si-NLRP3 and pIRES2-EGFP-NLRP3 significantly accelerated the wound closure compared with the corresponding negative control groups (Fig. 5A). In the Transwell migration assays, the number of migrated glioma cells in the si-NLRP3 group was significantly decreased compared with untransfected group and si-NC groups (Fig. 5B). Accordingly, pIRES2-EGFP-NLRP3 transfection significantly increased cell migratory abilities in SHG44 and A172 glioma cell lines (Fig. 5B). The results of the Transwell invasion assays revealed that, compared with
the untransfected and si-NC groups, si-NLRP3 significantly reduced the number of glioma cells that invaded through the Matrigel-coated membrane at 48 h, whereas pIRES2-EGFP-NLRP3 significantly promoted the invasiveness of glioma cells (Fig. 5C).

**Regulatory effects of NLRP3 on intracellular inflammasome activation, EMT and the AKT pathway in glioma cells.** Western blot analysis was performed on molecules of the NLRP3 inflammasome complex, ASC, pro-caspase-1 and pro-IL-1β, and molecules that indicate inflammasome activation, cleaved-caspase-1 (p20) and mature IL-1β (17 kDa) in SHG44 and A172 glioma cell lines. The protein bands of pro-caspase-1 and cleaved-caspase-1 (p20) were visualized using the same primary antibodies against caspase-1 at 50 and 25 kDa, respectively. Similarly, pro-IL-1β and mature IL-1β were visualized using the same primary antibodies against IL-1β at 35 and 17 kDa, respectively. Compared with the untransfected and si-NC groups, si-NLRP3 transfection significantly decreased the protein expression of all molecules of the

---

**Figure 4. Effect of NLRP3 on SHG44 and A172 glioma cell apoptosis.** The apoptotic glioma cells labeled with Annexin V-APC and 7-AAD were detected by flow cytometry. Values of apoptosis rate were expressed as the mean ± standard deviation (n=3). **P<0.01 and ***P<0.001. A representative apoptosis plot from three experiments performed is shown. NLRP3, NLR family pyrin domain containing 3; APC, allophycocyanin; 7-AAD, 7-Aminoactinomycin D; NC, negative control; EGFP, enhanced green fluorescent protein.
NLRP3 inflammasome complex, and cleaved-caspase-1 and mature IL-1β. Furthermore, NLRP3 overexpression significantly increased the expression levels of all 6 inflammasome complex-associated markers compared with the untransfected and pRES2-EGFP negative control groups (Fig. 6).

As indicated by the aforementioned results, NLRP3 demonstrated an intimate association with tumor malignancies involving apoptosis, proliferation, migration and invasion in human glioma cells. EMT is widely regarded as a major contributor to increased tumor metastasis, resulting in a higher capacity of cellular migration and invasion (19,20). Furthermore, cellular junctions serve an essential role in structural connection, which may be involved in cancer metastasis (21). The major components of tight junctions include ZO-1 and claudin-1. To further explore the facilitative effect of NLRP3 on the migration and invasion of glioma cells, western blot analysis assays were performed on molecules associated with EMT and cellular tight junctions. The results revealed that si-NLRP3 significantly downregulated the expression levels of mesenchymal proteins (N-cadherin and vimentin) and EMT-associated transcription factor Snail-1, while it upregulated the expression of epithelial markers and cellular tight junctions proteins (E-cadherin, ZO-1 and claudin-1) compared with the untransfected and si-NC groups. Compared with the untransfected and control vector groups, the pIRES2-EGFP-NLRP3 group significantly reduced E-cadherin, ZO-1 and claudin-1 protein expression, and increased the expression of N-cadherin, vimentin and snail-1 (Fig. 7).

The AKT signaling pathway has been associated with the development of glioma malignancies via its inhibitory effect on apoptosis, as well as its promoter roles on proliferation,
migration and invasion (22,23). As indicated in Fig. 8, p-AKT (Ser473), p-AKT (Thr308) and p-GSK3β (Ser9) expression levels were significantly reduced in the si-NLRP3 group, and significantly increased in NLRP3-overexpressing glioma cells compared with untransfected groups and negative control groups. Notably, no marked differences in total AKT and GSK3β protein levels were noted in the knockdown and overexpression experiments. Furthermore, the si-NLRP3 groups reduced p-PTEN levels, while overexpression of NLRP3 significantly attenuated the phosphorylation of PTEN with no marked differences observed on total PTEN protein expression in glioma cell lines (Fig. 8).

Discussion

The expression and function of the NLRP3 has been previously investigated in inflammatory and autoimmune diseases (6,7). Notably, there is an increasing amount of evidence indicating...
an important role of NLRP3 in the carcinogenesis of various tumors; however, the results appear to be inconsistent among different types of cancer (10-12,15,24-26). NLRP3 tissue expression and its function in glioma remain unclear.

In the present study, upregulated protein expression of NLRP3, ASC, caspase-1 and IL-1β in human glioma tissue was significantly associated with higher WHO grades as confirmed using immunohistochemical assays. These results provided a foundation for further NLRP3 functional studies and suggesting a promising role for NLRP3 in glioma progression. Furthermore, western blot assays demonstrated that NLRP3 significantly affected the expression of other constructive molecules of the inflammasome complex, including ASC, caspase-1 and pro-IL-1β, as well as inflammasome-activated status markers, cleaved-caspase1 and mature IL-1β. These finding implied that the overexpression of NLRP3 in human glioma may elevate the expression of other inflammasome complex proteins and the cellular inflammasome-activated...
status. Subsequently, the in vitro biological function experiments and western blot assays identified that NLRP3 participated in the regulation of glioma cellular proliferation, apoptosis, migration, invasion, EMT and the PTEN/AKT signaling pathway.

A previous study reported that the assembly and activation of the NLRP3 inflammasome complex, constructed of NLRP3, ASC, caspase-1 and pro-IL-1β proteins, functions as a negative regulator in the carcinogenesis of colitis-associated cancer (27). In hepatocellular carcinoma (HCC), the NLRP3 inflammasome complex was identified to be downregulated and its upregulation induced by the 17β-estradiol/estrogen receptor β/mitogen-activated protein kinase signaling pathway attributes to inhibition of HCC cell malignancy (14,24). However, Wang et al (17) reported that NLRP3 expression, but not inflammasome activation, is required for the EMT process.

Figure 8. Regulatory effects of NLRP3 on the PTEN/AKT signaling pathway in glioma cells. (A) Western blotting was used to determine the level of proteins associated with PTEN/AKT signaling pathway, including total AKT, p-AKT (Ser473), p-AKT (Thr308), GSK3β, p-GSK3β (Ser9), and its regulators p-PTEN (Ser380) and total PTEN. (B) The intensity of protein bands was measured and the values are presented as the mean ± standard deviation (n=3). *P<0.05. NLRP3, NLR family pyrin domain containing 3; NC, negative control; EGFP, enhanced green fluorescent protein; AKT serine/threonine kinase; GSK3β, glycogen synthase kinase-3β; PTEN, phosphatase and tensin homolog.
in colorectal cancer cells through regulation of Snail-1. It was also suggested that NLRP3 contributes to renal fibrosis by promoting transforming growth factor-β signaling and R-Smad activation, independent of inflammasome activation and cleaved-caspase-1 production in renal tubular epithelial cells (16). In lung cancer, NLRP3 mediates the release of IL-1β and IL-18 through a caspase-1-dependent or independent pathway (28). NLRP3 also enhances the proliferation and migration of A549 cells, the activation of phosphorylation of AKT and the expression of E-cadherin (28). The contradiction in the aforementioned studies suggests that NLRP3 may affect tumorigenesis and progression independent of its involvement in the inflammasome complex.

As one of the most important effectors of the NLRP3 inflammasome upon activation, IL-1β is an essential cytokine in the glioma inflammatory microenvironment (29), and considered a potent enhancer of glioma proliferation and metastasis (30-32). Tarassishin et al (33) reported that human glioma cells produce IL-1β upon highly sensitive NLRP3 inflammasome activation; however, in human normal astrocytes, NLRP3 inflammasome activation and mature IL-1β protein production are suppressed almost entirely, indicating that the ability of glioma cells to activate the NLRP3 inflammasome and produce IL-1β may lead to the development of an aggressively oncogenetic phenotype (33).

Numerous signaling pathways are involved in regulating the malignant anti-apoptotic and proliferative characteristics of glioma, of these molecular mechanisms the AKT signaling pathway is particularly important (34-36). The mutation/deletion of the tumor suppressor PTEN is an inhibitive regulator of the AKT signaling pathway (37,38). Furthermore, EMT is considered one of the most important processes that contribute to glioma progression and metastasis (19,20). Consistent with the aforementioned studies, the observations in the present study identified that NLRP3 functioned as a promoter of glioma cell migration and invasion by increasing Snail-1 expression, subsequently inducing EMT. Additionally, NLRP3 alleviated cellular apoptosis, promoted cell proliferation upon activation of the AKT signaling pathway and resulted in a reduction in PTEN phosphorylation.

A previous study suggested that the induction of p-PTEN induces a loss of PTEN activity, resulting in the activation of the AKT signaling pathway (39). Mizushima et al (40) demonstrated that NLRP3-/- mice exhibited diminished signal transducer and activator of transcription 3 (STAT3) expression in an inflammasome-independent way. STAT3 is a transcription factor that regulates various genes, including polo like kinase 1 (PLK1), a phosphatase of PTEN that leads to its inactivation and blockade of AKT signaling pathway (41,42). In addition, the upregulation of STAT3 enhances Snail expression (43), and increased Snail-1 expression was observed in the NLRP3 overexpression model used in the present study. Thus, we hypothesized that the NLRP3/STAT3/PLK1 signaling axis is involved in the regulation of NLRP3 on the PTEN/AKT signaling pathway. In parallel, reduced Smad2 phosphorylation combined with less Smad2/3 translocation have been reported in NLRP3-deficient B6lpr mice (44). Furthermore, reduced Smad2/3 phosphorylation results in decreased binding with Smad4 and impaired translocation of the Smad2/3/4 complex into the nucleus (45,46). The Smad complex has been confirmed as a direct binding site-targeted PTEN genetic promoter, which subsequently regulates PTEN transcription (45,46). There appears to be multiple pathways and complex crosstalk connecting NLRP3 to PTEN/AKT. The results of the present study indicate that NLRP3 regulates glioma malignancy through enhanced inflammasome activation, and undefined inflammasome-independent mechanisms that target EMT and the AKT signaling pathway by inducing PTEN phosphorylation. The in depth regulatory mechanism between NLRP3 and PTEN remains to be explored, and will be the focus of our future investigations.

To the best of our knowledge, this is the first study to investigate the association between NLRP3 protein expression and the WHO grades of human glioma. The findings of the present study suggest that NLRP3 may function as a tumor promoter, and that the aberrant activation of the AKT signaling pathway and EMT process caused by NLRP3 upregulation may provide a novel insight into the underlying mechanism of NLRP3 in glioma malignancy.

Acknowledgements

The authors would like to thank Professor Songtao Qi, Professor Yawei Liu and Dr Guozhong Yi (Department of Neurosurgery, Nanfang Hospital, Southern Medical University) for providing experimental suggestion and technical aid in immunohistochemical analysis of human glioma tissue samples.

Funding

The present study was supported by grants from the Guangdong Natural Science Foundation (grant no. 2016A030313525), Science and Technology Program of Guangzhou (grant no. 201607010015) and Presidential Foundation of Nanfang Hospital, Southern Medical University (grant no. 2017C024). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

YRQ and XFY conceived and designed the study; XFY, QZ, ZYC, SC, KFL and YL performed the experiments; XFY, QZ, HFW, HXW, HXL and CMK contributed to chemical analysis of human glioma tissue samples. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Ethics approval and consent to participate

The Ethics Committee of the Nanfang Hospital, Southern Medical University approved the experimental protocols, and all patients provided written informed consent for the use of their tissues in the present study.
Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Wen PY and Reardon DA: Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol 12: 69-70, 2016.
2. Mao J, Li D, Zhang H and You C: MicroRNA-485 inhibits malignant biological behaviour of glioblastoma cells by directly targeting PAK4. Int J Oncol 51: 1521-1532, 2017.
3. Omoju DeAngelis LM: Glioblastoma and other malignant gliomas: A clinical review. JAMA 310: 1842-1850, 2013.
4. Olar A and Sulman EP: Molecular markers in low-grade glioma-toward tumor reclassification. Semin Radiat Oncol 25: 155-163, 2015.
5. Christofides A, Kosmopoulos M and Piperic I: Pathophysiologi- cal mechanisms regulated by cytokines in gliomas. Cytokine 71: 377-384, 2015.
6. Strovink T, Heno-Mejia J, Elinav E and Flavell R: Inflammasomes in health and disease. Nature 481: 278-286, 2012.
7. Lamkanfi M and Dixit VM: Mechanisms and functions of inflammasomes. Cell 157: 1031-1022, 2014.
8. Haneke M, O'Neill LA and Coll RC: Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: Recent developments. Curr Opin Immunol 25: 40-45, 2013.
9. He Y, Hara H and Núñez G: Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci 41: 1012-1021, 2016.
10. Kent A and Blander JM: Nod-like receptors: Key molecular switches in the commodrum of cancer. Front Immunol 5: 185, 2014.
11. Terlizzi M, Casolaro V, Pinto A and Sorrentino R: Inflammasome: Cancer's friend or foe? Pharmacol Ther 143: 24-33, 2014.
12. Paugh SW, Botten EL, Savic D, Ramsey LB, Thierfelder WE, Gurung P, Malireddi RK, Acts M, Mayasundari A, Min J, et al: NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet 47: 607-614, 2015.
13. Schneider SL, Ross AL and Grichnik JM: Do inflammatory pathways drive melanomagenesis? Exp Dermatol 24: 86-90, 2015.
14. Wei Q, Guo P, Mu K, Zhang Y, Zhao W, Hua W, Qiu Y, Li T, Ma X, Liu Y, et al: Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome. Lab Invest 95: 805-816, 2015.
15. Sharma N and Jha S: NLR-regulated pathways in cancer: Opportunities and obstacles for therapeutic interventions. Cell Death Dis 5: e10343, 2014.
16. Wang W, Wang X, Chun J, Vilaysane A, Clark S, French G, Bracey NA, Trpkov K, Bonsi D, Suttijet H, et al: Inflammasome-independent NLRP3 requirement for epithelial-mesenchymal transition in colon cancer cells. Exp Cell Res 342: 184-192, 2016.
17. Louis DN, Ogha K, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
18. Kahlert UD, Nikkhah G and Maciackz J: Epithelial-to-mesenchymal- (E-M) transition as a relevant molecular event in malignant gliomas. Cancer Lett 331: 131-138, 2013.
19. Ling G, Ji Q, Ye W, Ma D and Wang Y: Epithelial-mesenchymal transition regulated by p38/MAPK signaling pathways participates in vasogenic mimicry formation in SHG44 cell transfected with TGF-β cDNA loaded lentivirus in vitro and in vivo. Int J Oncol 49: 2387-2398, 2016.
20. Zhuang Y, Peng H, Maestv J and Chen W: MicroRNA regulation of epithelial-mesenchymal transition and clinical consequence: MicroRNA regulation of epithelial junction proteins and clinical consequence. Mediators Inflamm 2016: 5078627, 2016.
21. Tang M, Zhao Y, Liu N, Chen E, Quan Z, Wu X and Luo C: Overexpression of HepaCAM inhibits bladder cancer cell proliferation and viability through the AKT/FoxO pathway. J Cancer Res Clin Oncol 143: 793-803, 2017.
22. Lim SY, Menzies AM and Rizos H: Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer 123 (S1): 2118-2129, 2017.
23. Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X, Zhao W, Hua W, Guo P and Han L: Deregulation of the NLRP3 inflammasome in hematopoietic parenchymal cells during liver cancer progression. Lab Invest 94: 52-62, 2014.
24. Kong H, Wang Y, Zeng X, Wang Z, Wang H and Xie W: Differential expression of inflammasomes in lung cancer cell lines and tissues. Tumour Biol 36: 7501-7513, 2015.
25. Wei Q, Li S, Li Y, Wang X, Liu B, Yu Q and Ma S: Curcumin attenuates glaucoma neurotoxicity in the hippocampus by suppression of ER stress-associated TXNIP/NLRP3 inflammasome activation in a manner dependent on AMPK. Toxicol Appl Pharmacol 286: 53-63, 2015.
26. Allen IC, TeKippe EM, Woodford RM, Uro NIS JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JP: The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 207: 1045-1056, 2010.
27. Wang H, Kong H, Zeng X, Liu W, Wang Z, Yan X, Wang H and Xie W: Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. Oncol Rep 35: 2053-2064, 2016.
28. Munoz L, Yeung YT and Grewal T: Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells. Cancer Biol Ther 17: 355-363, 2016.
29. Fathima Hurmath K, Ramaswamy P and Nandakumar DN: IL-1β microenvironment promotes proliferation, migration, and invasion of human glioma cells. Cell Biol Int 38: 1415-1422, 2014.
30. Sun W, Depping K and Johann W: Interleukin-1β promotes hypoxia-induced apoptosis of glioblastoma cells by inhibiting hypoxia-inducible factor-1 mediated adrenomedullin production. Cell Death Dis 5: e1020, 2014.
31. Tarassishin L, Lim J, Weatherly DB, Angeletti RH and Lee SC: Interleukin-1β-induced changes in the glioblastoma secretome suggest its role in tumor progression. J Proteomics 99: 152-168, 2014.
32. Tarassishin L, Casper D and Lee SC: Aberrant expression of interleukin-1β and inflammasome activation in human malignant gliomas. PLoS One 9: e103432, 2014.
33. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant phenotype through EGFR-Pi3K-AKT activation. Cancer Biol Ther 8: 1045-1054, 2009.
34. Song H, Zhang Y, Liu N, Zhao S, Kong Y and Yuan L: miR-92a-3p exerts various effects in glioma and glioma stem-like cells, especially towards CD133+β-catenin and Notch-1/Akt signaling pathways. Int J Mol Sci 17: E1799, 2016.
35. Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E and Wang L: PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7: 33440-33450, 2016.
36. Mueller S, Philips J, Onar-Thomas A, Romero E, Zheng S, Wiernek JK, McBride SM, Cowdrey C, Prados MD, Weiss WA, et al: PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro-oncology 14: 1146-1152, 2012.
37. Moon SH, Kim DK, Cha Y, Jeon I, Song J and Park KS: PI3K/Akt and Stat3 signaling pathways are controlled by PTEN expression of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Int J Oncol 42: 921-928, 2013.
38. Zhang Y, Wang Y, Sun P, Wang QZ, Wang DS, Zhang DS, Wang FH, Fu JH, Xu RH and Li YH: Fibrinogen promotes malignant biological tumor behavior involving epithelial-mesenchymal transition via the p-AKT/β-mTOR pathway in esophageal squamous cancer cells. J Cancer Res Clin Oncol 143: 2413-2424, 2017.
39. Mizushima Y, Shibasaki K, Usui F, Karasawa T, Kawashima A, Kohira H, Kobayashi M, Komada T, Inouye Y, Muto N: NLRP3 protein deficiency exacerbates hyperoxia-induced lethality through Stat3 protein signaling independent of interleukin-1β. J Biol Chem 290: 5065-5077, 2015.
40. Morris CJ, Kawamura E, Gillespie JA, Balgi A, Kannan N, Miram JS, Roberge M and Dedhar S: STAT3 regulates centrosome clustering in cancer cells via Stat3/PLK1. Nat Commun 5: 15289, 2014.
42. Cao YY, Yu J, Liu TT, Yang KX, Yang LY, Chen Q, Shi F, Hao JJ, Cai Y, Wang MR, et al: Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling. Cell Death Dis 9: 17, 2018.

43. Saitoh M, Endo K, Furuya S, Minami M, Fukasawa A, Imamura T and Miyazawa K: STAT3 integrates cooperative Ras and TGF-β signals that induce Snail expression. Oncogene 35: 1049-1057, 2016.

44. Lech M, Lorenz G, Kalkarni OP, Grosser MO, Stigrot N, Darisipudi MN, Günthner R, Wintergerst MW, Anz D, Susanti HE, et al: NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-β receptor signalling. Ann Rheum Dis 74: 2224-2235, 2015.

45. Xiong S, Cheng JC, Klausen C, Zhao J and Leung PC: TGF-β1 stimulates migration of type II endometrial cancer cells by downregulating PTEN via activation of SMAD and ERK1/2 signaling pathways. Oncotarget 7: 61262-61272, 2016.

46. Eritja N, Felip I, Dosil MA, Vigezzi L, Mirantes C, Yeramian A, Navaridas R, Santacana M, Llobet-Navas D, Yoshimura A, et al: Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-beta in mouse endometrium. Cell Death Differ 24: 1443-1458, 2017.